Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 4/20 | 0.68 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | KARS1 | Q15046 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.42 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CCR1 | P32246 | 1/20 | 0.41 |
| ▸ | CCR8 | P51685 | 1/20 | 0.41 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3609216 | 0.82 | CYP2A6 (1.00) | CYP2A6CYP19A1KARS1ALKKMT2A | |
| SCHEMBL2239691 | 0.80 | CYP2A6 (0.63) | CYP2A6CYP19A1KDM4ECCR1CCR8 | |
| SCHEMBL31127370 | 0.80 | CCR1 (0.58) | CYP2A6LMNATGFBR1KMT2ACCR1 | |
| SCHEMBL2242901 | 0.80 | CCR1 (0.58) | CYP2A6LMNATGFBR1KMT2ACCR1 | |
| SCHEMBL15452761 | 0.78 | CYP19A1 (0.49) | CYP2A6CYP19A1LMNAKDM4EHTT | |
| SCHEMBL25458413 | 0.77 | ALDH1A1 (0.54) | CYP2A6CYP19A1LMNAKDM4EHTT | |
| SCHEMBL9217242 | 0.77 | LMNA (0.58) | CYP2A6LMNAHTTTGFBR1KMT2A | |
| SCHEMBL2239121 | 0.77 | CYP2A6 (0.59) | CYP2A6CYP19A1LMNAKDM4EHTT | |
| SCHEMBL19009235 | 0.76 | CYP2A6 (0.81) | CYP2A6CYP19A1KARS1ALKKMT2A | |
| SCHEMBL4631312 | 0.76 | LMNA (0.67) | CYP2A6CYP19A1LMNAKDM4EHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2231642-B1 | PYRIMIDINES AS KINASE INHIBITORS | NOVARTIS AG (CH) | 2013-10-23 | — | — | EP | disclosed |
| CN-101490038-B | Pyrimidine derivatives as ALK-5 inhibitors | NOVARTIS AG | 2013-08-14 | — | — | CN | disclosed |
| US-8431578-B2 | Organic compounds | NOVARTIS AG (CH) | 2013-04-30 | — | — | US | disclosed |
| EP-2044056-B1 | PYRIMIDINE DERIVATIVES AS ALK-5 INHIBITORS | NOVARTIS AG (CH) | 2012-08-22 | — | — | EP | disclosed |
| US-7989458-B2 | Pyrimidine derivatives as alk-5 inhibitors | NOVARTIS AG (CH) | 2011-08-02 | — | — | US | disclosed |
| CN-101910153-A | Pyrimidines as kinase inhibitors | NOVARTIS AG | 2010-12-08 | — | — | CN | disclosed |
| US-20100298337-A1 | Organic Compounds | NOVARTIS AG (CH) | 2010-11-25 | — | — | US | disclosed |
| EP-2231642-A1 | PYRIMIDINES AS KINASE INHIBITORS | Novartis AG (CH) | 2010-09-29 | — | — | EP | disclosed |
| US-20090209539-A1 | Pyrimidine derivatives as alk-5 Inhibitors | NOVARTIS AG (CH) | 2009-08-20 | — | — | US | disclosed |
| CN-101490038-A | Pyrimidine derivatives as ALK-5 inhibitors | NOVARTIS AG (CH) | 2009-07-22 | — | — | CN | disclosed |
| WO-2009087224-A1 | PYRIMIDINES AS KINASE INHIBITORS | NOVARTIS AG (CH) | 2009-07-16 | — | — | WO | disclosed |
| EP-2044056-A1 | PYRIMIDINE DERIVATIVES AS ALK-5 INHIBITORS | Novartis Ag (CH) | 2009-04-08 | — | — | EP | disclosed |
| WO-2008006583-A1 | PYRIMIDINE DERIVATIVES AS ALK-5 INHIBITORS | NOVARTIS AG (CH) | 2008-01-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100298337-A1 | Organic Compounds | CYP11B2, TNNT2, CPT1B | CYP2A6 221/4885CYP19A1 1025/4885LMNA 795/4885 |
| US-20090209539-A1 | Pyrimidine derivatives as alk-5 Inhibitors | ALK, ACVR1, MUSK | CYP2A6 1225/4885CYP19A1 3779/4885LMNA 1528/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.